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INTRODUCTION
Inflammatory bowel diseases (IBDs) are multifactorial
disorders resulting from an abnormal immune response
driven by the presence of normal luminal flora. IBDs are
associated with the production of nonspecific mediators of
inflammation that initiate inflammatory processes and
tissue destruction (1-3). Crohn’s disease (CD) and ulcerative
colitis (UC) are the two main forms of IBDs.
An accepted hypothesis for IBD pathogenesis is that an
uncorrected balance between the host defenses and the
commensal microbiota in the gut of CD and UC patients
might promote the disease by causing bacterial invasion,
inflammation and loss of tolerance (4). A key role in the host
defense is performed by the intestinal epithelium, which
acts as a physical barrier that limits the access of enteric
microbes that are able to produce endogenous antimicrobial
peptides (AMPs) (5).
Human defensins, which are classified as a-defensins (HDs)
and b-defensins (HBDs) based on the arrangement of three
disulfide bridges (6), are antimicrobial peptides that represent
a wide spectrum of activity against pathogens. Human b-
defensin-1 (hBD-1), the first described b-defensin, is character-
ized by antimicrobial, chemotactic and immuno-enhancing
activities (7-9). The hBD-1 protein, which is encoded by the
DEFB1 gene (8p23.1), is constitutively expressed by epithelial
cells of a wide variety of tissues, but its expression can vary
between individuals and can be modified during the
inflammatory process. A decrease in hBD-1 expression was
reported in the mucosa of CD and UC patients (10-12).
Impaired production of defensins appears to contribute to
the pathogenesis of IBDs (13,14), and a correlation between
DEFB1 expression and single-nucleotide polymorphisms
(SNPs) present in the regulatory region of the gene has
been reported (15,16). Therefore, we analyzed the possible
association of 59 untranslated region (UTR) DEFB1 SNPs,
namely c.-52G.A (rs1799946) c.-44C.G (rs1800972) and c.-
20G.A (rs11362), with the susceptibility to inflammatory
bowel diseases in a group of Italian IBD patients (CD and
UC) and healthy control patients.
MATERIAL AND METHODS
Patients and controls
We enrolled 145 patients with inflammatory bowel disease
(93 males, mean age at diagnosis 37.18¡14.11; 52 females,
mean age at diagnosis 37.36¡16.35). Among the IBD
patients, 108 suffered from Crohn’s disease (mean age at
diagnosis 36.52¡14.01) and 37 suffered from ulcerative
colitis (mean age at diagnosis 38.24¡15.66). A total of 130
healthy adult blood donors (63 M/67F, mean age 31,3¡12.36)
with no history of IBDs and from the same ethnic origin as the
IBD patients were recruited and used as controls.
The IRCCS Burlo Garofolo Ethical Committee approved
the study (prot n. CIB 15/07, 03/03/2008).
The diagnosis of Crohn’s or UC disease was established by
following the European Crohn’s and Colitis Organisation
(ECCO) Consensus guidelines for IBDs (https://www.
ecco-ibd.eu/) (17,18) and the protocols of the Inflammatory
Bowel Disease and Functional Bowel Disorders Review Group
(http://www.cochrane.uottawa.ca/ibd/default.htm) (19).
DEFB1 SNP genotyping
Genomic DNA was extracted from peripheral whole blood
with the EZ1 DNA blood kit (Qiagen, Milan, Italy) following
the manufacturer’s instructions. The three polymorphisms
(rs1799946, rs1800972 and rs11362) in the 59UTR region of the
DEFB1 gene were genotyped by direct sequencing with Big
Dye Terminator chemistry and an ABI 3130 DNA Sequencer
(Applied Biosystems, Foster City, CA) using primers and
protocols previously described in the literature(20,21). The
sequences were analyzed with the 4peaks software (http://
www.mekentosj.com/science/4peaks).
Statistical analyses
The allele and genotype frequencies were calculated by
direct gene counting and compared by the Fisher exact test
using 2X2 and 3X2 contingency tables. The haplotype
frequencies were obtained according to the EM algorithm
using the Arlequin software (22) (version 3.11). The odds
ratios (O.R.) and 95% confidence intervals (C.I.) were also
calculated. The Bonferroni correction for multiple tests was
applied when required, and only corrected p,0.05 were
considered to be statistically significant. The R package
(www.r-project.org) was used for all the statistical analyses.
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RESULTS
No statistically significant differences were observed in
the distribution of the genotypic or allelic frequencies of the
DEFB1 c.-52G.A and c.-44C.G SNPs among the CD, UC
and healthy control subjects (Table 1). For the DEFB1 c.-
20G.A SNP, no significant differences in the allelic or
genotype frequencies were observed between the UC
patients and the healthy controls. A slight difference was
observed in the allelic distribution with a higher frequency
of the c.-20G.A G allele in the healthy subjects than in the
CD patients (62% vs. 53%; uncorrected p= 0.04; O.R. = 0.676;
95% C.I. = 0.461-0.992). Smaller differences were also
observed for the other genotypes. These differences, how-
ever, did not retain statistical significance after Bonferroni
correction. The three DEFB1 SNPs were observed to be in
linkage disequilibrium (p,0.05, D’.0.7) in the CD, UC or
control subjects and combined into three major haplotypes
(G/C/A; A/C/G; G/G/G) with a frequency .0.05 and
three minor haplotypes (A/G/G; G/C/G; A/C/A) with a
frequency ,0.05 (Table 2). No statistically significant
differences were observed when comparing the CD and
UC patients with the controls.
For 73 of the 108 CD patients, a classification of the disease
according to the bowel-disease anatomical localization was
also possible: 25 patients (34%) presented ileal CD, 30 (41%)
presented ileocolonic CD and 18 (25%) presented colonic CD.
The DEFB1 c.-52G.A G allele was more frequent in the
patients with ileal localization than in the healthy control
patients (78% vs. 58%; uncorrected p= 0.010, O.R. = 2.552; 95%
C.I. = 1.215-5.781), which was also observed with the GG
genotype (64% versus 30%, uncorrected p= 0.002; O.R. = 4.106;
95% C.I. = 1.554-11.521).
The C allele of the DEFB1 c.-44C.G SNP was more
frequent in the patients with colonic localization than in
the healthy subjects (94% vs. 78%; uncorrected p= 0.037;
O.R. = 4.773; 95% C.I. = 1.113-20.473), which was also
observed with the CC genotype (89% vs. 59%; uncorrected
p= 0.017; O.R. = 5.633; 95% C.I. = 1.242-52.507).
The DEFB1 c.-20G.A G allele was more frequent in the
control patients (62%) than in the colonic patients, (44%)
(uncorrected p= 0.046; O.R. = 0.485; C.I. = 0.224-1.038), which
was also observed with the GG genotype (p= 0.03, O.R. = 0.222;
95% C.I. = 0.024-1.013).
However, the statistical significances of all the compar-
isons were lost after applying Bonferroni’s correction.
When analyzing the haplotype frequencies, we observed
a different distribution of the three major haplotypes
between CD colonic patients and healthy control patients
(uncorrected p= 0.039). This difference was even greater
Table 1 - Allele and genotype count (and frequencies) of 59UTR DEFB1 single-nucleotide polymorphisms in Crohn’s
disease patients, ulcerative colitis patients and healthy controls. The Crohn’s disease patients are also stratified
according to the anatomical localization of the disease. The p-values,0.05 (uncorrected), odds ratios (ORs) and 95% CIs
are also reported.
DEFB1
SNPs CD Patients
UC
patients
Healthy
Controls
Ileal CD
n.25
Ileo-colonic
CD n.30
Colonic CD
n.18
total CD
n.108
total UC
n.37
total HC
n.30
-52G.A
Alleles
G 39/50 (0.78) # 34/60 (0.57) 21/36 (0.58) 137/216 (0.63) 44/74 (0.60) 151/260 (0.58)
A 11/50 (0.22) 26/60 (0.43) 15/36 (0.42) 79/216 (0.37) 30/74 (0.40) 109/260 (0.42)
Genotypes
GG 16/25 (0.64) ## 9/30 (0.30) 6/18 (0.33) 44/108 (0.41) 14/37 (0.38) 39/130 (0.30)
GA 7/25 (0.28) 16/30 (0.53) 9/18 (0.50) 49/108 (0.45) 16/37 (0.43) 73/130 (0.56)
AA 2/25 (0.08) 5/30 (0.17) 3/18 (0.17) 15/108 (0.14) 7/37 (0.19) 18/130 (0.14)
-44C.G
Alleles
C 39/50 (0.78) 49/60 (0.82) 34/36 (0.94) $ 179/216 (0.83) 59/74 (0.80) 203/260 (0.78)
G 11/50 (0.22) 11/60 (0.18) 2/36 (0.06) 37/216 (0.17) 15/74 (0.20) 57/260 (0.22)
Genotypes
CC 14/25 (0.56) 19/30 (0.63) 16/18 (0.89) $$ 71/108 (0.66) 22/37 (0.60) 76/130 (0.59)
CG 11/25 (0.44) 11/30 (0.37) 2/18 (0.11) 37/108 (0.34) 15/37 (0.40) 51/130 (0.39)
GG 0/25 0/30 0/18 0/108 0/37 3/130 (0.02)
-20G.A
Alleles
G 22/50 (0.44) 36/60 (0.60) 16/36 (0.44)* 114/216 (0.53)** 43/74 (0.58) 162/260 (0.62)
A 28/50 (0.66) 24/60 (0.40) 20/36 (0.56) 102/216 (0.47) 31/74 (0.42) 98/260 (0.38)
Genotypes
GG 4/25 (0.16) 9/30 (0.30) 2/18 (0.11)*** 25/108 (0.23) 12/37 (0.33) 47/130 (0.36)
GA 14/25 (0.56) 18/30 (0.60) 12/18 (0.67) 64/108 (0.59) 19/37 (0.51) 68/130 (0.52)
AA 7/25 (0.28) 3/30 (0.10) 4/18 (0.22) 19/108 (0.18) 6/37 (0.16) 15/130 (0.12)
# Ileal CD vs. HC, p=0.01, O.R. = 2.552 (1.215-5.781);
## Ileal CD vs. HC, p= 0.002, O.R. = 4.106 (1.554-11.521);
$ Colonic CD vs. HC, p= 0.037, O.R. = 4.773 (1.113-20.473);
$$ Colonic CD vs. HC, p= 0.017, O.R. = 5.633 (1.242-52.507);
*Colonic CD vs. HC, p= 0.046, O.R. = 0.485 (0.224-1.038);
**CD vs. HC, p= 0.04, O.R. = 0.676 (0.461-0.992);
***Colonic CD vs. HC, p= 0.03, O.R. = 0.222 (0.024-1.013).
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when the minor haplotypes were also included in the
analysis (uncorrected p,0.001). (Table 2).
DISCUSSION
To our knowledge, only one study has previously investi-
gated the role of DEFB1 SNPs in Crohn’s disease (23). The
frequencies of the DEFB1 SNPs in CD patients reported by
Kocsis et al. are comparable to the frequencies reported by our
study. Moreover, similar to our study, the authors failed to
observe any association between the c.-52G.A and c.-20G.A
DEFB1 SNPs and the overall susceptibility to CD. For the c.-
44C.G SNP, they observed a different distribution between
the CD and control patients with an increased frequency of the
c.-44C.G GG genotype in the control patients (12%) com-
pared with the CD patients (4%). This difference was not
observed in our study; however, none of the CD patients in
our study presented the c.-44C.G GG genotype, whereas
three (2%) of the control patients, which were matched for sex,
age and ethnicity, presented the genotype.
In addition, Kocsis et al. (23) reported several significant
associations between the DEFB1 SNPs and the anatomical
localization of Crohn’s disease (ileal, ileocolonic or colonic).
For the DEFB1 c.-44C.G SNP, Kocsis et al. observed a
significant increase in the CC genotype in ileocolonic
patients and to a lesser extent in colonic but not ileal
patients compared with healthy control patients. Our results
indicate an increased frequency of the CC genotype in
the colonic patients (89% vs. 59% in control patients).
Additionally, a slight increase in the CC genotype frequency
was observed in the ileocolonic patients (63% vs. 59% in
control patients), but not in ileal.
Kocsis et al. (23) also showed that the GG genotype (c.-
20G.A SNP) was more frequent in control subjects than in
patients with colonic CD. Our results appear to confirm
these findings. Because colonic CD localization has been
associated with impaired hBD-1 expression and because the
c.-20G.A A allele appears to be associated with reduced
levels of DEFB1 expression, it can be hypothesized that this
polymorphism might cause lower hBD-1 expression in
colonic epithelial cells.
For c.-52G.A, Kocsis et al. (23) did not report any
difference between patients with different localization of CD
and controls. Conversely, we observed that the GG
genotype was more frequent in the ileal CD patients (64%)
than in the controls (30%), but the difference was not
statistically significant.
The constitutive expression of hBD-1, which is known to
be a constitutively expressed peptide, has already been
reported in CD and UC patients. Moreover, stressful events
could regulate DEFB1 mRNA levels, (24-27) which could be
relevant for the intestinal mucosa. The presence of 59UTR
DEFB1 SNPs may be able to explain interindividual changes
in DEFB1 expression, and these differences may be able to
account for different susceptibility to diseases (such as CD).
However, the mechanism by which the same DEFB1 SNP
can be associated with the development of the disease in a
specific anatomical region and not in others remains
unknown. Variations in hBD-1 production among different
intestinal traits of CD and UC patients are more likely to
result from the actions of other genes or factors involved in
the regional regulation of the hBD-1 peptide (24-27) rather
than as a direct consequence of a single SNP or a
combination of SNPs to form haplotypes.
We are aware that the loss of statistical significance of the
p-values after correcting for multiple tests comparisons,
which is possibly due to the limited number of samples
analyzed, is likely the major weakness of this study.
However, it is noteworthy that our results confirm the
findings previously reported by another research group
(23), which indicate that DEFB1 may a contributing factor to
susceptibility to Crohn’s disease.
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Table 2 - Haplotype counts (and frequencies) of 5’UTR DEFB1 polymorphisms in Crohn’s disease patients, ulcerative
colitis patients and healthy controls. The Crohn’s disease patients are also stratified according to the anatomical
localization of the disease. The p-values (uncorrected) ,0.05 are also indicated.
DEFB1 Haplotypes
-52G.A/-44C.G/-20G.A CD patients UC patients
Healthy
Controls
Ileal CD
n.25
Ileo-colonic
CD n.30
Colonic CD
n.18
total CD
n.108
total UC
n.37
total HC
n.30
Major (freq.0.05)
G/C/A 28/50 (0.56) 23/60 (0.38) 19/36 (0.53)#* 100/216 (0.46) 30/74 (0.41) 112/260 (0.43)
A/C/G 11/50 (0.22) 25/60 (0.42) 13/36 (0.36)#* 76/216 (0.35) 28/74 (0.39) 99/260 (0.38)
G/G/G 11/50 (0.22) 11/60 (0.18) 1/36 (0.02)#* 36/216 (0.17) 14/74 (0.19) 50/260 (0.19)
Minor (freq,0.05)
A/G/G 0 0 1/36 (0.02)* 1/216 (0.004) 1/74 (0.01) 0
G/C/G 0 0 1/36 (0.02)* 1/216 (0.004) 0 0
A/C/A 0 1/60 (0.01) 1/36 (0.02)* 2/216 (0.009) 1/74 (0.01) 0
# Colonic CD vs. HC major haplotypes, p= 0.039.
*Colonic CD vs. HC major+minor haplotypes, p= 0.0004595.
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